Startup profile · funding coverage
TestDynamics funding, valuation and investors
Vendor-neutral imaging-AI evaluation, integration and governance for hospitals and radiology groups.
Verified company research · funding, investors and latest developments
Keep track of TestDynamics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A announced; amount represents issuer's $9M funding disclosure, Series A tranche not separately specified
$9M disclosed funding (tranche split undisclosed) · November 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$9M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Austin, Texas, United States
Investors in latest funding
Lead: Healthier Capital
Other: Cedars-Sinai Technology Ventures
Overview
Austin, Texas-based TestDynamics announced on 16 November 2026 that it secured $9M in funding, with its Series A led by Healthier Capital and Cedars-Sinai Technology Ventures participating. The original release does not expressly split an individual Series A tranche from other funding.
Its Satori platform helps hospitals independently evaluate third-party imaging algorithms on de-identified local studies, integrate selected tools with radiology systems and monitor results after rollout. TestDynamics reports clinical use at several large US medical centers, but names, clinical outcomes, revenue and pricing are not independently confirmed.
Why TestDynamics is interesting
Hospitals need to test, buy, monitor and replace competing FDA-cleared imaging algorithms; Satori offers one clinical contract and connector rather than one procurement/integration per algorithm. The disclosed $9M covers a financing announcement involving a Series A, not necessarily a fully specified $9M Series A tranche.
Product & use cases
Illustrative hospital workflow from TestDynamics's published Satori implementation stages (not a hands-on test): (1) clinical AI committee sets imaging use cases and measurable goals; (2) sign one contract and BAA, deploy Satori Edge connected to PACS, worklists and reporting systems; (3) test candidate FDA-cleared algorithms side-by-side on the hospital's de-identified studies, with clinician review; (4) integrate selected results in Satori View while radiologists approve findings before reporting; (5) monitor drift, clinician overrides, usage and performance after launch, retaining ability to swap poorly performing vendors. Vendor publishes staged 2–6 week connections, up-to-30-day algorithm trials and 90-day value review as typical process, not proven SLA. Enterprise price is quote-based/undisclosed.
- Hospital comparison and local validation of competing medical imaging algorithms
- Single-contract radiology AI procurement and clinical system integration
- Postdeployment drift monitoring, clinician overrides and reporting
Key facts
- Issuer Business Wire release 2026-11-16: $9M funding announced, Series A led by Healthier Capital; Cedars-Sinai Technology Ventures participated. https://www.businesswire.com/news/home/20261116497451/en/
- The original release does not state the new Series A tranche size separately, so $9M is recorded as total announced funding, not a mathematically proven single-round amount.
- Vendor Satori implementation stages and single BAA/PACS workflow: https://testdynamics.net/platform/
- Vendor-selected clinical-use claims must not be interpreted as clinical outcome evidence or FDA clearance for the Satori platform.
Funding history (newest first)
Series A announced; amount represents issuer's $9M funding disclosure, Series A tranche not separately specified
2026-11-16 $9M disclosed funding (tranche split undisclosed)- Healthier Capital (lead)
- Cedars-Sinai Technology Ventures (participant)
Source: Read source · businesswire.com
Competitive landscape
Edge: Satori combines vendor-neutral evaluation and ongoing monitoring with procurement and integrations; vendor independence, local-data generalizability and outcome improvements require external validation.
One contract does not prove cheaper net total costs; algorithm/vendor fees, deployment, oversight, BAA and governance require review. No published price or independent comparative sensitivity/specificity. Vendor says Satori uses cleared algorithms but does not itself analyze images or claim its own FDA clearance. The 2026-11-16 issuer wording 'secured $9M in funding, with its Series A...' leaves tranche versus cumulative distinction unresolved.
-
Direct imaging AI vendor purchases incumbent
Each vendor's own contract/integration/benchmarks; Satori offers cross-vendor program management.
-
Hospital-built algorithm evaluation program alternative
Clinical team can run independent studies with local PACS and analytics, but incurs staff/integration costs.
-
Blackford Analysis direct
Medical imaging AI platform/marketplace; compare vendor neutrality, workflow and evaluation methods.
-
Nuance Precision Imaging Network adjacent
Enterprise imaging AI distribution/integration ecosystem; commercial and validation models differ.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.